The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival

In conclusion, our study suggests that VEGFR-2 inhibitors might be one of the best candidates for molecular therapy against recurre nt meningiomas.
Source: Brain Tumor Pathology - Category: Neurology Source Type: research